5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies
暂无分享，去创建一个
A. Palumbo | H. Dombret | B. Quesnel | P. Hérait | A. Stathis | C. Preudhomme | X. Thomas | K. Yee | C. Récher | E. Zucca | N. Vey | T. Facon | K. Rezai | E. Raffoux | C. Thieblemont | L. Karlin | C. Gomez-Roca | M. Michallet | S. Amorim | Y. Peng | Y. Peng